Depletion of PD-1-positive cells ameliorates autoimmune disease

[1]  M. Aringer,et al.  Effector Mechanisms in Autoimmunity , 2020, The Autoimmune Diseases.

[2]  Tiefeng Xu,et al.  An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells , 2018, Theranostics.

[3]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[4]  Reporting for specific materials, systems and methods , 2018 .

[5]  B. Murray,et al.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2—Surveillance for Treatment Complications and Disease Progression , 2017, American Journal of Neuroradiology.

[6]  R. Mehra,et al.  Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer , 2017, Journal of Immunotherapy for Cancer.

[7]  D. Atanackovic,et al.  An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle. , 2017, Molecular pharmaceutics.

[8]  Tiefeng Xu,et al.  Engineering of a self-adjuvanted iTEP-delivered CTL vaccine , 2017, Acta Pharmacologica Sinica.

[9]  D. Mukhopadhyay,et al.  Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells , 2016, Journal of Cell Science.

[10]  D. Vignali,et al.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. , 2016, Immunity.

[11]  Kristin N. Parent,et al.  A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers , 2016, Theranostics.

[12]  F. Lublin,et al.  Novel Agents for Relapsing Forms of Multiple Sclerosis. , 2016, Annual review of medicine.

[13]  Xiaoyuan Chen,et al.  Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding , 2016, Theranostics.

[14]  K. Myhr,et al.  Disease-modifying treatments for multiple sclerosis – a review of approved medications , 2015, European journal of neurology.

[15]  J. Cochran,et al.  Cell-Binding Assays for Determining the Affinity of Protein-Protein Interactions: Technologies and Considerations. , 2016, Methods in enzymology.

[16]  I. Pastan,et al.  New Life for Immunotoxin Cancer Therapy , 2015, Clinical Cancer Research.

[17]  M. P. Moore,et al.  Response to Comment on Hughes et al. An Early Pregnancy HbA1c ≥5.9% (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women at Increased Risk of Adverse Pregnancy Outcomes. Diabetes Care 2014;37:2953–2959 , 2015, Diabetes Care.

[18]  S. Gettinger,et al.  Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy , 2015, Diabetes Care.

[19]  J. Kolls,et al.  Anti-CD20 Antibody Therapy and Susceptibility to Pneumocystis Pneumonia , 2015, Infection and Immunity.

[20]  I. Pastan,et al.  An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. , 2014, Leukemia research.

[21]  J. Konkel,et al.  In Vivo–Generated Antigen-Specific Regulatory T Cells Treat Autoimmunity Without Compromising Antibacterial Immune Response , 2014, Science Translational Medicine.

[22]  Soumitra S Ghosh,et al.  Novel Exenatide Analogs with Peptidic Albumin Binding Domains: Potent Anti-Diabetic Agents with Extended Duration of Action , 2014, PloS one.

[23]  D. Wingerchuk,et al.  Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. , 2014, Mayo Clinic proceedings.

[24]  M. Atkinson,et al.  Type 1 diabetes , 2014, The Lancet.

[25]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[26]  T. Okazaki,et al.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application , 2013, Nature Immunology.

[27]  V. Kuchroo,et al.  Using EAE to better understand principles of immune function and autoimmune pathology. , 2013, Journal of autoimmunity.

[28]  J. Kaplan,et al.  Immune status following alemtuzumab treatment in human CD52 transgenic mice , 2013, Journal of Neuroimmunology.

[29]  I. Pastan,et al.  A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity , 2012, Molecular Cancer Therapeutics.

[30]  V. Kuchroo,et al.  Immune checkpoints in central nervous system autoimmunity , 2012, Immunological reviews.

[31]  Susan S. Kim,et al.  Belimumab in systemic lupus erythematosus: an update for clinicians , 2012, Therapeutic advances in chronic disease.

[32]  C. Massilamany,et al.  Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers , 2011, BMC Immunology.

[33]  I. Pastan,et al.  Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes , 2011, Proceedings of the National Academy of Sciences.

[34]  A. Cardona,et al.  Isolation of brain and spinal cord mononuclear cells using percoll gradients. , 2011, Journal of visualized experiments : JoVE.

[35]  M. V. von Herrath,et al.  Type 1 diabetes: etiology, immunology, and therapeutic strategies. , 2011, Physiological reviews.

[36]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[37]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[38]  Jeffrey A. Bluestone,et al.  Genetics, pathogenesis and clinical interventions in type 1 diabetes , 2010, Nature.

[39]  U. Brinkmann.  Disulfide-Stabilized Fv Fragments , 2010 .

[40]  J. Bluestone,et al.  Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal , 2009, Nature Immunology.

[41]  Lieping Chen,et al.  PD‐1 ligands expressed on myeloid‐derived APC in the CNS regulate T‐cell responses in EAE , 2008, European journal of immunology.

[42]  L. Abrahmsén,et al.  Engineering of a femtomolar affinity binding protein to human serum albumin. , 2008, Protein engineering, design & selection : PEDS.

[43]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[44]  Urso FORTE. Urso.  HIGHLIGHTS OF PRESCRIBING INFORMATION , 2007 .

[45]  J. Bluestone,et al.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway , 2006, The Journal of experimental medicine.

[46]  A. Cooke,et al.  Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells1 , 2006, The Journal of Immunology.

[47]  T. Zimmerman,et al.  Simultaneous metal chelate affinity purification and endotoxin clearance of recombinant antibody fragments. , 2006, Journal of immunological methods.

[48]  S. Khoury,et al.  Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[49]  T. Okazaki,et al.  Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Okumura,et al.  Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN-γ-Induced Nitric Oxide Production1 , 2005, The Journal of Immunology.

[51]  S. Miller,et al.  Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis , 2005, Nature Medicine.

[52]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[53]  G. Freeman,et al.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  L. Adorini,et al.  Dynamics of Pathogenic and Suppressor T Cells in Autoimmune Diabetes Development , 2003, The Journal of Immunology.

[55]  G. Freeman,et al.  Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.

[56]  S. Khoury,et al.  Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis , 2003, The Journal of experimental medicine.

[57]  S. Khoury,et al.  The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.

[58]  D. Pardoll,et al.  Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 , 2002, The Journal of Immunology.

[59]  S. Khoury,et al.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. , 2001, The Journal of clinical investigation.

[60]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[61]  G. Nolan,et al.  Production of high-titer helper-free retroviruses by transient transfection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[62]  W. Paul,et al.  DNP-Lys-ficoll: a T-independent antigen which elicits both IgM and IgG anti-DNP antibody-secreting cells. , 1975, Journal of immunology.